Front section exposes by Bloomberg/CNBC on ISRG illuminating: Northland Capital analyst Kalia recommended EDAP as BUY w/ISRG as Under
Suggest one seriously digest all those articles above as well as commentaries from surgeons using the Da Vinci along with Mass General having only one DaVinci!
Juxtapose the above with the EDAP CEO's commentary about localized prostate cancer and evolving urological methodology and it should become clearer.
On Northland Capital's (Twin Cities) website you'll see verification that analyst Kalia who follows the Medical Technology space of 17 companies has IMPACT: EDAP is one of five Opening Buy Recommendations while
ISRG is one of six UnderPerform rating in his MedTech universe!
Noticed for EDAP some other UNCOVERED large geographic markets: China; Japan.
Came across Nymox (NYMX) a Ph 2 DRUG for treating localized prostate cancer: financing issue and needs to
do Ph3! no long term followup studies were noted in my perusal.